[ONE COURSE OF PEMBROLIZUMAB AFTER RADIATION THERAPY WAS VERY EFFECTIVE AGAINST METASTATIC BLADDER CANCER AND CR WAS CONFIRMED: A CASE REPORT].

A 78-year-old man was referred to our institution for the evaluation of macroscopic hematuria and a bladder tumor for which we initially performed a transurethral resection of the bladder tumor. Pathological examination revealed that the tumor was a high-grade invasive urothelial carcinoma that was at least stage T2. Computed tomography scan showed a bladder carcinoma with no nodal or distant metastases. Assuming radical cystectomy, we administered two courses of neoadjuvant chemotherapy (i.e., gemcitabine and cisplatin chemotherapy). Unfortunately, the bladder tumor metastasized to the right internal iliac lymph node. We performed consolidative radiotherapy (54 Gy/ 27 fractions to the bladder area containing the right internal iliac lymph node). One month later, bilateral lung metastases and local penile infiltration appeared; thus, second-line chemotherapy (pembrolizumab) was added to the regimen. The patient rejected further chemotherapy after the first course of pembrolizumab. A computed tomography scan performed four months after one course of pembrolizumab therapy showed complete resolution of the metastatic lesions. As of this writing, 20 months after the first course of pembrolizumab, the patient continues to be in complete remission.

[INVASIVE BLADDER CANCER PRODUCING GRANULOCYTE-COLONY STIMULATING FACTOR: A CASE REPORT].

A 72-year-old man presented with the chief complaint of asymptomatic macroscopic hematuria. Cystoscopy revealed a non-papillary sessile tumor in the left bladder wall. Computed tomography revealed a large invasive tumor in the bladder and left hydronephrosis; no metastases were observed. Laboratory examination showed leukocytosis (27,600 /µl) and a high serum level of granulocyte-colony stimulating factor (G-CSF; 158 pg/ml). A diagnosis of locally advanced bladder cancer producing G-CSF was made; therefore, the patient underwent a total cystectomy and urinary diversion with an ileal conduit. Histopathological examination of the surgical specimen revealed a urothelial carcinoma with squamous differentiation (pT3a, pN0, ly1, v1). In terms of their immunohistochemistry, the tumor cells were shown to express G-CSF. After surgery, the leukocyte count and serum level of G-CSF decreased to normal values. No recurrence was observed in the 41 months after surgery without adjuvant therapy. We reviewed 73 cases of bladder cancer producing G-CSF reported in the literature in Japan.